Exibindo 1801 - 1830 de 2728
O CoronaFatos chega ao seu último episódio. Apesar da pandemia ainda não ter acabado, especialistas já apontam sinais de que podemos estar saindo da fase mais aguda dela e entrando em um novo estágio no enfrentamento da Covid-19. Ainda não é possível ter certeza se haverá novas ondas de infecções provocadas pelo coronavírus ou não, mas com a esperança de que dias melhores estejam chegando, especialmente graças às vacinas, o CoronaFatos finaliza um ciclo em uma fase em que temos informação de qualidade sobre as formas de prevenir e combater a doença. E para terminar o podcast neste momento e…
Article
A sessão do Centro de Estudos do Instituto Oswaldo Cruz (IOC/Fiocruz) da próxima sexta-feira (4/3) abordará o tema Petrópolis, a cidade imperial do Brasil: história, desenvolvimento sustentável e crises ambientais, com a pesquisadora da Casa de Oswaldo Cruz (COC/Fiocruz), Magali Romero Sá, e o especialista em Direito Ambiental, Marcus de Almeida Lima. Na ocasião, o pesquisador do Laboratório de Virologia Comparada e Ambiental do IOC, José Paulo Gagliardi Leite, atuará como mediador.
Devido ao distanciamento social recomendado pelas autoridades de saúde, a atividade será transmitida pelo Canal…
Article
Countries with high vaccination coverage are adopting a dangerous rhetoric according to which the pandemic is over or almost over. But how can one state that when there are still 70,000 people dying of COVID-19 in a week, worldwide? The warning was issued by the Assistant Director-General for Access to Medicines and Pharmaceutical Products of the World Health Organization (WHO), Brazilian Mariângela Batista Galvão Simão. At the Advanced Seminars on Global Health and Health Diplomacy, of the Fiocruz Global Health Center (CRIS/Fiocruz), Simão highlighted last Wednesday (23/2) that it is indeed…
Article
When he was about to turn 4 years old, Julinho started to attend a day care center near his home. The adaptation was difficult for the adults in the family, who were used to taking care of him all the time. “What if he had a seizure?”, “What if he cried a lot?”, “What if they forgot the medication schedule?”. The questions were frequent. But the boy surprised everyone with his good integration: he didn't seem to miss his mother and grandmother, he was kind to his classmates and encouraged all the time to try new things. Even chicken with cassava, which he previously disliked, became his…
Article
In this role for less than five months, the new Ecuador ambassador in Brazil, Carlos Alberto Velástegui, visited Fiocruz last Friday (February 18) to strengthen the ties between his country and the Foundation. In the company of consul Marco Larrea, he was welcomed by Fiocruz president, Nísia Trindade Lima, and showed interest in defining areas for possible cooperation with Ecuador institutions and in getting to know more about the production of vaccines against COVID-19 and other diseases.
Nísia Trindade Lima and ambassador Velástegui (center) talked about scientific cooperation (Image: …
Article
The Oswaldo Cruz Foundation (Fiocruz), through the Immunobiological Technology Institute (Biomanguinhos), provides the first doses of the COVID-19 vaccine (recombinant) produced with the national Active Pharmaceutical Ingredient (API). The first batch of national vaccines was released by the internal quality control of Bio-Manguinhos on 2/14.
“The release of the first 100% Brazilian COVID-19 vaccines, now available to the Ministry of Health, is a milestone in Brazilian self-sufficiency and the strengthening of the Health Economic-Industrial Complex (CEIS in the Portuguese acronym). Having…
Article
This Thursday (17/2) the Fiocruz Genomic Network released new figures on the lineages and variants of the Sars-CoV-2 virus in Brazil. The data are computed every week on the Network’s platform, using data obtained from the EpiCoV platform, from GISAID (Global Initiative on Sharing All Influenza Data), an international platform used to share the genomic data of influenza and Sars-CoV-2 viruses.
The Fiocruz Genomic Network site gathers data about lineages and variants of the Sars-CoV-2 virus in Brazil (Image: Josué Damacena - IOC/Fiocruz)
As previously observed, the Omicron variant is…
Article
A Fundação Oswaldo Cruz, por meio do Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos/Fiocruz), disponibiliza para o Ministério da Saúde (MS) as primeiras doses da vacina Covid-19 (recombinante) produzidas com o Ingrediente Farmacêutico Ativo (IFA) nacional. O primeiro lote de vacinas nacionais foi liberado pelo controle de qualidade interno de Bio-Manguinhos/Fiocruz no dia 14 de fevereiro.
As pouco mais de 550 mil doses disponibilizadas já compõem as entregas da Fiocruz contratadas pelo Ministério da Saúde para 2022 (foto: Bio-Manguinhos/Fiocruz)
“A liberação das primeiras…
Article
A Fiocruz Brasília e o Ministério Público do Distrito Federal e Territórios (MPDFT) assinaram, na última sexta-feira (11/2), um acordo de cooperação para o desenvolvimento do projeto Territórios da Construção de Si: processos de desinstitucionalização de jovens e adolescentes pela maioridade. O foco do projeto é a garantia dos direitos de jovens em situação de risco e vulnerabilidade social – em especial, aqueles que se encontram acolhidos em abrigos institucionais da Assistência Social do DF.
Quando atingem os 18 anos, os adolescentes devem deixar os abrigos, e estudar esse processo de…
Article
O CoronaFatos está chegando ao fim da sua temporada e neste episódio o programa faz uma espécie de 'resumão' com tudo o que você precisa saber sobre o atual momento da pandemia de Covid-19. A pandemia ainda não acabou e não é possível ter certeza sobre o caminho que ela tomará. Mas com a visualização de uma possível trégua na fase mais aguda da crise, o programa fala sobre como estão as curvas de casos e de mortes provocadas pelo coronavírus, aborda a hipótese da transformação da emergência sanitária em endemia, reforça os cuidados de prevenção que ainda são necessários e esclarece dúvidas…
Article
A technological innovation may contribute to the quest for the leprosy elimination, one of the humanity oldest diseases. An international team of scientists, led by the Oswaldo Cruz Institute (IOC/Fiocruz), in partnership with Microsoft AI for Health and the Novartis Foundation, has developed a diagnostic assistant, based on artificial intelligence, which can help identify suspected leprosy lesions. The technology has been called AI4Leprosy.
Photographer records skin lesion on project volunteer (Photo: Fareed Mirza/AI4Leprosy)
An article published in the scientific journal The Lancet…
Article
Looking at the map, the distance between the countries is big. Within the American continent, Mexico is the Spanish-speaking country that is farthest away from Brazil. But the two nations are closer to each other than it may seem. Fiocruz and Mexican institutions have joint projects, a cooperation that can expand even further, judging by the interest demonstrated by consul Héctor Humberto Valezzi Zafra. Together with the deputy consul in Rio de Janeiro, Ana Luisa Vallejo Barba, the diplomat was received by Fiocruz president Nísia Trindade Lima last Thursday (February 10th) at the Official…
Article
COVID-19 diagnostics, therapeutics, and vaccines are powerful reminders: health technologies can help to shape the way in which societies control disease. Challenges in ensuring global, equitable access to these fruits of biomedical research and development (R&D) during the COVID-19 pandemic have highlighted the urgency of reorienting the system towards the public interest. The first step is a clearer articulation of what R&D in the global public interest is. That is what we seek to do here.
There are four major concerns about biomedical R&D, despite its impressive technological…
Article
In a geopolitical context marked by disputes and inequalities, there are many economic, social, and environmental challenges in the path of those aiming to reduce these inequalities and achieve better global health outcomes. Based on this point of view, issues such as multilateralism and a possible new world order were discussed last Thursday (February 10) during the first Advanced Seminar in Global Health and Health Diplomacy this year. Promoted by the Fiocruz Global Health Center (CRIS/Fiocruz), the webinar brought together three specialists to discuss perspectives for 2022.
“Health is not…
Article
A study analyzed the geographic distribution and the incidence of co-infection with a human T-lymphotropic virus (HTLV) and a human immunodeficiency virus (HIV) in Bahia, which is an endemic state for both retroviruses. The research was carried out using all samples submitted to serological tests at the Central Public Health Laboratory of Bahia (Lacen-BA), from 2004 to 2013. The total was about 130,000 samples from 358 of the 417 municipalities in Bahia. The research results, coordinated by Fiocruz Bahia researcher Maria Fernanda Grassi, were published in the Frontiers in Medicine journal. In…
Article
As reported by the State Health Secretariats of Rio de Janeiro and Santa Catarina, Fiocruz has identified three cases of the BA.2 lineage of the Omicron variant, using genetic sequencing. Two of the cases occurred in Rio de Janeiro and the other in the southern state of Santa Catarina. The findings were confirmed by the Laboratory of Measles and Respiratory Viruses of the Oswaldo Cruz Institute (IOC/Fiocruz), a national reference center for respiratory viruses for the Brazilian Ministry of Health, which has been mapping genomes of the virus since early in the pandemic. The laboratory is part…
Article
The Fiocruz Genomic Network has released new data on the status of lineages and variants of the Sars-CoV-2 in Brazil, based on the genomic surveillance produced by the Network and by other initiatives. According to the publication, while in December 39.4% of sequenced genomes belonged to the Omicron variant, in January 2022 this rate rose to 95.9%. The variant has now been found in all of the country’s regions. The Network Report shows that omicron now fully dominates the epidemiological scenario of Covid-19 in Brazil. It also highlights technological innovations developed by the Fiocruz…
Article
Celebrated last Sunday (January 30), the World Neglected Tropical Diseases Day draws attention to infections that affect more than one billion people worldwide, and yet receive little in terms of attention and investment. These diseases, such as Chagas disease, dengue fever, leishmaniasis, hanseniasis, schistosomiasis and worm-related illnesses, affect mostly poor people, resulting in death or in great health problems, worsening people’s quality of life as they make it harder to remain in school and in the workforce.
Selenium was evaluated for the first time in patients with chronic Chagas…
Article
When a new advisory group of the World Health Organization (WHO) for neglected diseases holds its first meeting this Friday, January 1st, there will be a Brazilian in the room. Thiago Moreno L. Souza, a researcher of the Center for Technological Development in Health (CDTS/Fiocruz), is one of the 14 participants from all over the world selected for the Strategic and Technical Advisory Group which will be working with the Working Group for Neglected Diseases for Access to Effective and Safe Drugs (STAG WGA).
Thiago Moreno Souza is one of the 14 participants from all over the world selected for…
Article
Researchers of the Albert Einstein College of Medicine, in the United States, in a partnership with the Oswaldo Cruz Institute (IOC/Fiocruz) and with the University of São Paulo (USP) and other institutions, have given an important step towards the finding of a treatment for yellow fever. Considered a worldwide trend, synthetic monoclonal antibodies have been the subject of studies all over the planet. These antibodies are laboratory products and bind to a specific region of the viral particle, interrupting the infection process.
(Image: Oswaldo Cruz Institute)
Drugs of this kind were…
Article
We all had some degree of hope that the end of 2021 and the beginning of 2022 would bring us the much-awaited retraction of the pandemic. However, the emergence of the new Omicron variant dragged us away from the end of the tunnel we were longing for. Many countries, including some with powerful health systems, excellent living conditions, and high levels of vaccination, are hitting record numbers of contagions every day.
So far, the challenge on the horizon for 2022 is to overcome the pandemic and the immense sanitary and socio-economic inequality, achieve social and economic recovery…
Article
Science, technology and innovation to create resiliency, recover the planet from the impacts of COVID-19 and prepare it to face future health crises, including the ones resulting from environmental problems. This was the focus of the Global Sustainable Technology and Inovation Conference (G-Stic), an international reference in the debate that relates science, technology and innovation to the 2030 Agenda, which took place in Dubai from January 17th to 19th, 2022. Fiocruz takes part in it since 2019, through Fiocruz Strategy for the 2030 Agenda (EFA 2030), being invited by G-Stic to be a cohost…
Article
At a moment in which the world is watching a new peak of COVID-19 cases, preliminary analysis of a study on safetey and immunogenicity indicate that the use of the AstraZeneca vaccine as a booster shot increases the immune response against the variants of concern Beta, Delta, Alpha, and Gamma. An analysis made separately with samples of the research also shows an increased response of antibodies against the Omicron variant, which is behind the new wave of the disease.
Preliminary analysis of a study indicate that the use of the AstraZeneca vaccine as a booster shot increases the immune…
Article
Com o objetivo de ampliar a divulgação de notícias sobre Covid-19 para pessoas com deficiências auditivas, a Coordenação de Comunicação Social (CCS/Fiocruz) lançou um programa semanal que reúne as principais notícias publicadas na Agência Fiocruz de Notícias (AFN) traduzidas para a Língua Brasileira de Sinais (Libras) e com áudio em português.
Confira outras edições do AFN Acessibilidade.
Article
This Friday (January 7), Fiocruz received assent from the National Agency of Sanitary Surveillance (Anvisa) for the alteration in the register of the COVID-19 vaccine (recombinant), which requested the addition of the Foundation as a producer of the Active Pharmaceutical Ingredient (API). After the transference of the AstraZeneca technology and with the approval of Anvisa, the Foundation is now the first institution in the country that is allowed to produce and distribute a 100% Brazilian COVID-19 vaccine to the Ministry of Health.
Up to this moment, Fiocruz has the equivalent of 21…
Article
A study published on medRXiv, this Wednesday (December 29th), shows that the four vaccines applied in Brazil provide a high degree of additional protection against symptomatic infections and severe cases of COVID-19 in people who had already contracted Sars-CoV-2 previously. The study, led by Julio Croda and Manoel Barral-Neto, Fiocruz researchers, also reinforces the importance of a full vaccination scheme, even for those people.
Vaccine production at Bio-Manguinhos (Image: Bernardo Portella/Bio-Manguinhos/Fiocruz)
As preprint (without peer review), Effectiveness of CoronaVac, ChAdOx1,…
Article
A third AstraZeneca vaccine dose significantly increases neutralizing antibodies levels against the Ômicron variant (B.1.1.529), a new study indicates. The research was conducted independently by researchers from different institutions, including Fiocruz and Oxford University. And these results were published in preprint form on the bioRxiv platform (Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses) on Thursday.
A third AstraZeneca vaccine dose significantly increases neutralizing antibodies levels against the Ômicron variant (Image:Peter Ilicciev)
"As we have…
Article